I think this is where, again, we have to develop the advisory committee. There is in existence a reference group already for the current scheme and for the consultations, potentially, on the development of the regulations.
What we will see is that when this bill and the regulations development come into force, as it were, we will hear from a lot of different people. There are many scientists and many experts, both in Canada and internationally, whom we can leverage.
Some of the concept includes that we will have an expert advisory committee, but we also have rosters of experts on very specific pathogens, people who are already on a roster and have agreed to provide us with expert advice as, if, and when needed, in a fairly nimble fashion.
We actually need rosters of experts not only for this particular bill or regulations; we will need them for a nimble response to emerging pathogens in any case. As you can imagine, we already have two Leishmania experts, and they will probably want to sign up to help us, because they'll be ready to provide input. So I think there are incentives on both sides to create a committee that is viable, up-to-date, and effective.
What we would like to do is, potentially, to draft a concept we can consult on—“What do you think of this concept of the structure of a committee?”—to see what the reactions are from our stakeholders.